Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3969 |
Name | thyroid gland papillary carcinoma |
Definition | A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated thyroid gland carcinoma thyroid gland papillary carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Ramucirumab | thyroid gland papillary carcinoma | not applicable | detail... |
RET rearrange | Sorafenib | thyroid gland papillary carcinoma | sensitive | detail... |
RET rearrange | Ponatinib | thyroid gland papillary carcinoma | sensitive | detail... |
PIK3CA E542K | MK2206 | thyroid gland papillary carcinoma | sensitive | detail... |
PIK3CA E542K | MK2206 + Temsirolimus | thyroid gland papillary carcinoma | sensitive | detail... |
BRAF V600E | RO5126766 | thyroid gland papillary carcinoma | sensitive | detail... |
Unknown unknown | Lenvatinib | thyroid gland papillary carcinoma | not applicable | detail... |
RET fusion | Selpercatinib | thyroid gland papillary carcinoma | sensitive | detail... |
BRAF act mut | Vemurafenib | thyroid gland papillary carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | thyroid gland papillary carcinoma | predicted - sensitive | detail... |
EML4 - NTRK3 | Entrectinib | thyroid gland papillary carcinoma | predicted - sensitive | detail... |
RET fusion | Pralsetinib | thyroid gland papillary carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | thyroid gland papillary carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT01534897 | Phase I | Dabrafenib | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | Completed | USA | 0 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | CAN | 8 |
NCT01709292 | Phase II | Vemurafenib | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT01723202 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT02145143 | Phase 0 | Vemurafenib | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | Active, not recruiting | USA | 0 |
NCT02211222 | Phase I | Lenvatinib | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | Approved for marketing | USA | 0 |
NCT02702388 | Phase II | Lenvatinib | Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Completed | USA | CAN | 14 |
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03002623 | Phase II | CUDC-907 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | Terminated | USA | 0 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Recruiting | USA | CAN | 1 |
NCT03469011 | Phase I | Imatinib | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | Recruiting | CAN | 0 |
NCT03914300 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Not yet recruiting | USA | 0 |
NCT04462471 | Phase I | Copanlisib + Vemurafenib | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | Recruiting | USA | 0 |
NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Not yet recruiting | USA | 0 |